I-131 MIBG Therapy for Advanced Stage III &amp;amp; IV Neuroblastoma

Riad, Raef; Kotb, Magdy; Omar, Walid; Zaher, Ahmed; Ebied, Emad; Pitman, Alexander G; Dayem, H.A.

doi:10.4236/jct.2011.24065

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In dosimetric studies that have been conducted, a wide range of whole-body and lesion absorbed doses have been observed from fixed or weight-based administrations of activity [9], and methods for performing dosimetry have differed. A variable response to treatment has been reported and although the treatment is usually given with palliative intent, complete responses have occasionally been reported [10,11]. A wide range of treatment protocols are followed, using either fixed activities (ranging from 3.7 GBq to 11.2 GBq), weight-based administrations considering a maximum level of 444 MBq/kg in the absence of stem cell rescue, to be modulated according to the haematological reserve, and 666 MBq/kg if stem cells were stored [12], or according to whole-body absorbed doses [4,7].…”

Section: Introductionmentioning

confidence: 99%

“…A wide range of treatment protocols are followed, using either fixed activities (ranging from 3.7 GBq to 11.2 GBq), weight-based administrations considering a maximum level of 444 MBq/kg in the absence of stem cell rescue, to be modulated according to the haematological reserve, and 666 MBq/kg if stem cells were stored [12], or according to whole-body absorbed doses [4,7]. An extremely wide range of absorbed doses have been quoted in the literature to tumours and to normal organs [9,11]. Treatment planning based on pre-therapy dosimetry calculations with I-124 and I-123 have been proposed [4,[13][14][15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours

et al. 2020

View full text Add to dashboard Cite

The purpose of the EANM Dosimetry Committee Series on "Standard Operational Procedures for Dosimetry" (SOP) is to provide advice to scientists and clinicians on how to perform patient-specific absorbed dose assessments. This SOP describes image and data acquisition parameters and dosimetry calculations to determine the absorbed doses delivered to whole-body, tumour and normal organs following a therapeutic administration of 131 I mIBG for the treatment of neuroblastoma or adult neuroendocrine tumours. Recommendations are based on evidence in recent literature where available and on expert opinion within the community. This SOP is intended to promote standardisation of practice within the community and as such is based on the facilities and expertise that should be available to any centre able to perform specialised treatments with radiopharmaceuticals and patient-specific dosimetry. A clinical example is given to demonstrate the application of the absorbed dose calculations.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Clinical applications include Na[ 131 I] for diagnosing and treating thyroid disease, both malignant and benign (Sawka, et al . 2009; Ross 2011) 131 I meta-iodobenzylguanidine (mIBG) for neuroendrocrine tumors (Riad 2011); 131 I-ethiodized oil for hepatocellular carcinoma (Ahmadzadehfar, et al 2011); and radiolabeled monoclonal antibodies for non-Hodgkins lymphoma (Calais and Turner 2012). Measurements of 131 I prior to administration are usually made in the hospital or radiopharmacy using activity calibrators (commonly called “dose calibrators”).…”

Section: Introductionmentioning

confidence: 99%

(Mis)use of 133 Ba as a calibration surrogate for 131 I in clinical activity calibrators

Zimmerman

Bergeron

2016

Applied Radiation and Isotopes

View full text Add to dashboard Cite

Using NIST-calibrated solutions of 131Ba and 131I in the 5 mL NIST ampoule geometry, measurements were made in three NIST-maintained Capintec activity calibrators and the NIST Vinten 671 ionization chamber to evaluate the suitability of using 133Ba as a calibration surrogate for 131I. For the Capintec calibrators, the 133Ba response was a factor of about 300% higher than that of the same amount of 131I. For the Vinten 671, the Ba-133 response was about 7 % higher than that of 131I. These results demonstrate that 133Ba is a poor surrogate for 131I. New calibration factors for these radionuclides in the ampoule geometry for the Vinten 671 and Capintec activity calibrators were also determined.

show abstract

Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine

Arora

Bandopadhyaya

2018

Ann Nucl Med

View full text Add to dashboard Cite

We present a comprehensive review of Neuroendocrine Tumors (NET) and the current and developing imaging and therapeutic modalities for NET with emphasis on Nuclear Medicine modalities. Subsequently, nanotechnology and its emerging role in cancer management, especially NET, are discussed. The article is both educative and informative. The objective is to provide an insight into the developments made in nuclear medicine and nanotechnology towards management of NET, individually as well as combined together.

show abstract

I-131 MIBG Therapy for Advanced Stage III & IV Neuroblastoma

Abstract: Radio-labelled MIBG therapy has been tried in the treatment of advanced stage III and IV neuroblastoma in an attempt

Cited by 4 publications

References 16 publications

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours

(Mis)use of 133 Ba as a calibration surrogate for 131 I in clinical activity calibrators

Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine

Contact Info

Product

Resources

About